



Autolus Therapeutics to Participate in Upcoming Investor Conferences

April 7, 2026 at 7:00 AM EDT

LONDON and GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that the Company will participate in two upcoming investor conferences.

25th Annual Needham Virtual Healthcare Conference

Date and time: April 13, 2028; 10:15am EDT / 3:15pm BST

Presenter: Chief Executive Officer Dr. Christian Itin

A webcast of the presentation will be available on the "Events" page in the "Investor Relations & Media" section of the Company's website at <https://www.autolus.com/investor-relations-media/events/>. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

Van Lanschot Kempen Life Sciences Conference

Management to host investor meetings

Date: April 16, 2026

Location: Amsterdam

About Autolus Therapeutics plc

Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.

Contact:

Amanda Cray

+1 617-967-0207

a.cray@autolus.com